Mount Sinai Logo

Olga Greengard

  • PROFESSOR (PART-TIME) Pediatrics, Infectious Diseases
  • PROFESSOR (PART-TIME) Pharmacology and Systems Therapeutics
Print ProfilePrint Profile

Biography

    E-mail: olga.greengard@mssm.edu
    Tel: (212) 241-6932

    Mailing Address
    One Gustave L. Levy Place, Box 1198, New York, NY 10029

Publications

Porotto M, Murrell M, Greengard O, Moscona A. Triggering of human parainfluenza virus 3 fusion protein (F) by the hemagglutinin-neuraminidase (HN) protein: an HN mutation diminishes the rate of F activation and fusion. J Virol. 2003 Mar; 77(6): 3647-3654.

Porotto M, Greengard O, Poltoratskaia N. A Human parainfluenza virus type 3 HN-receptor interaction: the effect of 4-GU-DANA on a neuraminidase-deficient variant. J Virol 2001; 75: 7481-7488.

Murrell M, Greengard O, Porotto M, Poltoratskaia N. A single amino acid alteration in the human parainfluenza virus type 3 HN confers resistance to both binding inhibition and neuramindiase inhibition by the antiviral agent 4-GU-DANA (Zanamivir). J Virol 2001; 75: 6310-6320.

Horga MA, Gusella GL, Greengard O, Poltoratskaia N, Porotto M, Moscona A. Mechanism of interference mediated by human parainfluenza virus type 3 infection. J Virol 2000 Dec; 74(24): 11792-11799.

Greengard O, Poltoratskaia N, Leikina E, Zimmerberg J, Moscona A. The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA. J Virol. 2000 Dec; 74(23): 11108-11114.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Greengard did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central